JP2018500375A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018500375A5 JP2018500375A5 JP2017534946A JP2017534946A JP2018500375A5 JP 2018500375 A5 JP2018500375 A5 JP 2018500375A5 JP 2017534946 A JP2017534946 A JP 2017534946A JP 2017534946 A JP2017534946 A JP 2017534946A JP 2018500375 A5 JP2018500375 A5 JP 2018500375A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- effective amount
- subject
- administered
- therapeutically effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 claims description 12
- 230000002092 calcimimetic effect Effects 0.000 claims description 9
- UHMPCVGLSKFXHR-NFZXMVPNSA-N (1r,3r)-5-[(2e)-2-[(3as,7ar)-1-[(2s)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-2-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CCC([C@]2(CCC1)C)[C@H](CCCC(C)(C)O)C)=C\C=C1C[C@@H](O)C(=C)[C@H](O)C1 UHMPCVGLSKFXHR-NFZXMVPNSA-N 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 208000037147 Hypercalcaemia Diseases 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 229940109239 creatinine Drugs 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000001631 haemodialysis Methods 0.000 claims description 2
- 230000000322 hemodialysis Effects 0.000 claims description 2
- 230000000148 hypercalcaemia Effects 0.000 claims description 2
- 208000030915 hypercalcemia disease Diseases 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 14
- VDHAWDNDOKGFTD-MRXNPFEDSA-N cinacalcet Chemical compound N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CCCC1=CC=CC(C(F)(F)F)=C1 VDHAWDNDOKGFTD-MRXNPFEDSA-N 0.000 description 1
- 229960003315 cinacalcet Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462098112P | 2014-12-30 | 2014-12-30 | |
| US62/098,112 | 2014-12-30 | ||
| US14/710,746 | 2015-05-13 | ||
| US14/710,746 US9539264B2 (en) | 2014-12-30 | 2015-05-13 | Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics |
| PCT/US2015/065175 WO2016109156A1 (en) | 2014-12-30 | 2015-12-11 | Use of 2-methylene-19-nor-(20s)-1a,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018500375A JP2018500375A (ja) | 2018-01-11 |
| JP2018500375A5 true JP2018500375A5 (enExample) | 2018-09-13 |
Family
ID=56162990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017534946A Pending JP2018500375A (ja) | 2014-12-30 | 2015-12-11 | 続発性副甲状腺機能亢進症を処置するための２−メチレン−１９−ノル−（２０Ｓ）−１α，２５−ジヒドロキシビタミンＤ３の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9539264B2 (enExample) |
| EP (1) | EP3240549A4 (enExample) |
| JP (1) | JP2018500375A (enExample) |
| AU (1) | AU2015374468A1 (enExample) |
| CA (1) | CA2969334A1 (enExample) |
| WO (1) | WO2016109156A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9539264B2 (en) * | 2014-12-30 | 2017-01-10 | Wisconsin Alumni Research Foundation | Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics |
| US10105375B2 (en) | 2016-08-30 | 2018-10-23 | Wisconsin Alumni Research Foundation | Combination of low dose 2-methylene-19-nor-(20S)1α, 25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040043971A1 (en) | 1995-04-03 | 2004-03-04 | Bone Care International, Inc. | Method of treating and preventing hyperparathyroidism with active vitamin D analogs |
| US5843928A (en) | 1997-03-17 | 1998-12-01 | Wisconsin Alumni Research Foundation | 2-alkylidene-19-nor-vitamin D compounds |
| US6306844B1 (en) | 1997-03-17 | 2001-10-23 | Wisconsin Alumni Research Foundation | Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength |
| US6136799A (en) | 1998-04-08 | 2000-10-24 | Abbott Laboratories | Cosolvent formulations |
| US6673782B2 (en) | 1999-04-29 | 2004-01-06 | Wisconsin Alumni Research Foundation | Treatment of systemic lupus erythematosis |
| CA2404335C (en) | 2000-03-27 | 2009-01-06 | Wisconsin Alumni Research Foundation | Vitamin d compounds used to stabilize kidney transplants |
| MXPA03000406A (es) | 2000-07-14 | 2003-06-06 | Wisconsin Alumni Res Found | Uso de 2-metilen-19-nor-20(s)-1 alfa,25-dihidroxivitamina d3 para incrementar la resistencia de los huesos. |
| US20080249068A1 (en) | 2002-09-05 | 2008-10-09 | Deluca Hector F | Method of Extending the Dose Range of Vitamin D Compounds |
| US20050124591A1 (en) | 2003-07-29 | 2005-06-09 | Jin Tian | Use of vitamin Ds to treat kidney disease |
| US20060171983A1 (en) | 2003-07-30 | 2006-08-03 | Jin Tian | Use of Vitamin D receptor activators or Vitamin D analogs to treat cardiovascular disease |
| US7704980B2 (en) | 2003-10-08 | 2010-04-27 | Wisconsin Alumni Research Foundation | Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds |
| US7214671B2 (en) | 2004-02-19 | 2007-05-08 | Wisconsin Alumni Research Foundation | Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases |
| EP1853274B1 (en) | 2005-02-11 | 2013-01-23 | Wisconsin Alumni Research Foundation | 2-methylene-19-nor- (20s-24s) - 1alpha, 25-dihydroxyvitamine-d2 |
| US20060276534A1 (en) | 2005-03-17 | 2006-12-07 | Amgen Inc. | Methods of decreasing calcification |
| EP2001832A1 (en) * | 2006-03-23 | 2008-12-17 | Amgen Inc. | Methods and compositions for making and using polymorphs of cinacalcet |
| DK3225243T3 (da) * | 2007-04-25 | 2025-09-29 | Opko Renal Llc | Metode til sikker og effektiv behandling og forebyggelse af sekundær hyperparatyreoidisme ved kronisk nyresygdom |
| CA2764577C (en) | 2009-08-03 | 2017-12-19 | Wisconsin Alumni Research Foundation | Method of preventing renal disease and treating symptoms thereof |
| CA2794006C (en) | 2010-03-23 | 2017-11-28 | Wisconsin Alumni Research Foundation | (20s)-2-methylene-19-nor-22-dimethyl-1.alpha.,25-dihydroxyvitamin d3 and (20r)-2-methylene-19-nor-22-dimethyl-1.alpha.,25-hydroxyvitamin d3 |
| AU2012335009B2 (en) * | 2011-11-10 | 2017-08-31 | Kai Pharmaceuticals, Inc. | Calcimimetics and methods for their use |
| US20130295083A1 (en) | 2012-05-02 | 2013-11-07 | Wisconsin Alumni Research Foundation | 2a-Methyl-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2AMD) or 2 methylene-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2MD) Support Survival and Function of Transplanted Islet Cells In Type 1 Diabetes |
| MY172886A (en) | 2012-06-29 | 2019-12-13 | Wisconsin Alumni Res Found | Use of 2-methylene-19-nor-(20s)-1?25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism |
| US9539264B2 (en) * | 2014-12-30 | 2017-01-10 | Wisconsin Alumni Research Foundation | Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics |
-
2015
- 2015-05-13 US US14/710,746 patent/US9539264B2/en not_active Expired - Fee Related
- 2015-12-11 JP JP2017534946A patent/JP2018500375A/ja active Pending
- 2015-12-11 WO PCT/US2015/065175 patent/WO2016109156A1/en not_active Ceased
- 2015-12-11 CA CA2969334A patent/CA2969334A1/en not_active Abandoned
- 2015-12-11 EP EP15875945.6A patent/EP3240549A4/en not_active Withdrawn
- 2015-12-11 AU AU2015374468A patent/AU2015374468A1/en not_active Abandoned
-
2016
- 2016-10-31 US US15/338,924 patent/US9814736B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015522015A5 (enExample) | ||
| JP2015096532A5 (enExample) | ||
| JP2016510343A5 (enExample) | ||
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| JP2018505882A5 (enExample) | ||
| JP2016518387A5 (enExample) | ||
| JP2015505564A5 (enExample) | ||
| JP2014528474A5 (enExample) | ||
| JP2014502641A5 (enExample) | ||
| JP2015517488A5 (enExample) | ||
| JP2012193216A5 (enExample) | ||
| JP2020521797A5 (enExample) | ||
| JP2013521303A5 (enExample) | ||
| JP2013523893A5 (enExample) | ||
| RU2015102831A (ru) | ПРИМЕНЕНИЕ 2-МЕТИЛЕН-19-НОР-(20S)-1α, 25-ДИГИДРОКСИВИТАМИНА D3 ДЛЯ ЛЕЧЕНИЯ ВТОРИЧНОГО ГИПЕРПАРАТИРЕОЗА | |
| JP2020534270A5 (enExample) | ||
| RU2016149316A (ru) | Лечение ревматоидного артрита | |
| CN115605194A (zh) | 过度炎症综合征的治疗 | |
| JP2018529766A5 (enExample) | ||
| JP2015522603A5 (enExample) | ||
| JP2018500375A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| JPWO2019241442A5 (enExample) | ||
| JP2019507786A5 (enExample) | ||
| JP2014522414A5 (enExample) |